

What is claimed is:

1. A tetrahydro-5-oxo-2-furancarboxylic acid salt of amlodipine.
- 5        2. The tetrahydro-5-oxo-2-furancarboxylic acid salt of amlodipine as defined in claim 1, wherein the tetrahydro-5-oxo-2-furancarboxylic acid is (S)-tetrahydro-5-oxo-2-furancarboxylic acid or (R)-tetrahydro-5-oxo-2-furancarboxylic acid.
- 10      3. A method for preparing amlodipine tetrahydro-5-oxo-2-furancarboxylate, in which amlodipine is reacted with tetrahydro-5-oxo-2-furancarboxylic acid in an inert solvent.
- 15      4. The method as defined in claim 3, wherein the tetrahydro-5-oxo-2-furancarboxylic acid is (S)-tetrahydro-5-oxo-2-furancarboxylic acid or (1R)-(-)-10-tetrahydro-5-oxo-2-furancarboxylic acid.
- 20      5. A pharmaceutical composition for the treatment of ischemic cardiac disorders or hypertension, comprising a therapeutically effective amount of the tetrahydro-5-oxo-2-furancarboxylic acid salt of amlodipine of claim 1 or 2, and a pharmaceutically acceptable diluent or carrier.
- 25      6. The pharmaceutical composition as defined in claim 5, wherein the composition is in the dosage form of tablets or capsules.
7. The pharmaceutical composition as defined in claim 5, wherein the composition is in the dosage form of solutions or injectables.